Search

Your search keyword '"Sakr, W."' showing total 319 results
Start Over Author "Sakr, W."
319 results on '"Sakr, W."'

15. 'Candidatus Phytoplasma phoenicium' in Libano

Author

Molino Lova, M., Abou Jawdah, Y., Choueiri, E., Geagea, L., Abdul Nour, H., Geze, N., Sobh, H., El Zammar, S., El Khoury, R., Nehme, M., El Amil, R., Fakhr, R., Haidar, A., Mortada, C., Alma, Alberto, Picciau, Luca, Tedeschi, Rosemarie, Vercesi, A., Casati, P., Perini, M., Maacaroun, R., Mahfoud, C., Mouannes, E., Sakr, W., and Bianco, P. A.

Subjects
Scopazzi del mandorlo, sintomatologia, diagnostica PCR, insetto vettore, lotta integrata
Published
2010

22. Maspin Reprograms the Gene Expression Profile of Prostate Carcinoma Cells for Differentiation

Author

Bernardo, M. M., primary, Meng, Y., additional, Lockett, J., additional, Dyson, G., additional, Dombkowski, A., additional, Kaplun, A., additional, Li, X., additional, Yin, S., additional, Dzinic, S., additional, Olive, M., additional, Dean, I., additional, Krass, D., additional, Moin, K., additional, Bonfil, R. D., additional, Cher, M., additional, Sakr, W., additional, and Sheng, S., additional

Published
2011
Full Text
View/download PDF

26. Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53, and CK19 in alcohol-fixed, embedded tissue

Author

Coltrera, M. D., Zarbo, R. J., Sakr, W. A., and Gown, A. M.

Subjects
Mouth, Hyperplasia, Tissue Fixation, Mouth Mucosa, Nuclear Proteins, Genes, p53, Immunohistochemistry, Antigens, Neoplasm, Proliferating Cell Nuclear Antigen, Mutation, Carcinoma, Squamous Cell, Humans, Keratins, Pharynx, Mouth Neoplasms, Precancerous Conditions, Research Article
Abstract

Recognition of premalignant lesions in the oral epithelium has the potential to increase survival rates for squamous cell carcinoma of the oral cavity. It has previously been reported that cytokeratin 19 (CK19), a 40-kd epithelial cytoskeletal protein within the suprabasal squamous epithelium, is a specific marker of moderate-to-severe dysplasia and carcinoma in situ in oral cavity squamous epithelium. In contrast, normal epithelium and hyperplastic lesions reportedly express CK19 only in the basal layer if at all. The authors chose to test and extend this hypothesis by studying suprabasal CK19 expression and dysplasia of the oral cavity and upper aerodigestive tract in paraffin-embedded specimens that had been fixed in alcohol, a superior fixative for the preservation of cytokeratins. The authors examined 56 alcohol-fixed, paraffin-embedded specimens including 37 from the oral cavity, using two antibodies specific for CK19 (Ks19.1 and 4.62), an antibody to the nuclear proliferation marker, proliferating cell nuclear antigen (PCNA) (19A2), and an antibody to the putative tumor suppressor gene, p53 (pAb1801). The lesions were classified as normal, hyperplasia, mild dysplasia, moderate dysplasia, severe dysplasia/carcinoma in situ, or invasive squamous cell carcinoma, following standard histologic criteria. Immunocytochemically stained sections were scored for the presence or absence of suprabasal CK19, suprabasal PCNA, and p53 positivity, regardless of location. The immunostaining patterns of the two anti-CK19 antibodies were essentially equivalent. Except for one laryngeal specimen, normal epithelium, when positive, showed CK19 expression only in scattered cells throughout the basal layer. Proliferating cell nuclear antigen-positive nuclei were found exclusively in the basal layer. In areas of hyperplasia, CK19 immunostaining was absent or confined to the basal layer in 20 of 38 specimens and was expressed in suprabasal cells in 18 of 38 hyperplastic specimens. Proliferating cell nuclear antigen immunostaining in all cases of hyperplasia was limited to the basal layer. Severe dysplasia and carcinoma in situ showed suprabasal CK19 staining in six of nine specimens and no CK19 staining in three of nine specimens. In contrast, suprabasal PCNA immunostaining was found in all dysplasia and carcinoma in situ cases. p53 expression was detected in three of nine severe dysplasia/CIS specimens and was immunocytochemically undetectable in all normal, hyperplasia, and mild to moderate dysplasia specimens. The authors conclude that suprabasal CK19 expression is neither a sensitive nor a specific marker of premalignancy in oral epithelium and cannot be used to distinguish hyperplasia from dysplasia. In contrast, a strong correlation between suprabasal expression of PCNA, a marker for proliferating cells, and dysplasia/carcinoma in situ was evident.(ABSTRACT TRUNCATED AT 400 WORDS)

Published
1992

30. Clinical trial of soy isoflavone supplementation before radical prostatectomy in patients with localized prostate cancer

Author

Kucuk, O., Sarkar, F., Sakr, W., Wood, D., Cher, M., Abrams, J., Doerge, D.D., Pollak, M.M., Djuric, Z., and Majumdar, A.

Subjects
Isoflavones -- Health aspects, Isoflavones -- Research, Prostate cancer -- Diet therapy, Prostate cancer -- Research, Food/cooking/nutrition
Abstract

Epidemiologic studies have shown an inverse association between dietary intake of soy products and prostate cancer (PCa) risk. We previously observed that soy isoflavone supplements stabilize disease in patients with advanced prostate cancer. To determine the effects of soy isoflavones on newly diagnosed organ-confined prostate cancer, we conducted a small randomized, placebo-controlled clinical trial. Our goal was to use surrogate endpoint biomarkers to investigate the biological effects of soy isoflavone supplementation in patients with localized prostate cancer. Twenty-eight men with newly diagnosed prostate cancer were randomly assigned to receive tablets (Novasoy) containing 200 nag soy isoflavone (n = 17) or no supplementation (n = 11) for 3 wk before radical prostatectomy. Biomarkers of cell proliferation and apoptosis were assessed by Western blot analysis in benign and cancerous prostate tissues. We assessed oxidative stress markers by measuring levels of peripheral blood lymphocyte DNA oxidation products and plasma 8-isoprostane. Usual dietary intake of nutrients was assessed by a food frequency questionnaire at baseline. Prostatectomy specimens were evaluated for pathologic stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepirhelial neoplasia (HGPIN). Plasma levels of soy isoflavones, insulin-like growth factor-l, insulin-like growth factor binding protein-3, and prostate specific antigen were measured at baseline and after 3 wk of supplementation or observation. There were no significant differences between the intervention and placebo groups with regard to tumor size (82% vs. 70%, 7, P = 0.24), or diffuse involvement of the prostate by HGP1N (94% vs 92%). The data from this small pilot study suggest that soy isoflavones may have different biological effects on different variables. Analysis of clinical and biomarker studies will be presented.

Published
2004

31. Prognostic significance of p53 gene mutations in laryngeal cancer.

Author

Chomchai JS, Du W, Sarkar FH, Jacobs JR, Ensley JF, Sakr W, Yoo GH, Chomchai, J S, Du, W, Sarkar, F H, Li, Y W, Jacobs, J R, Ensley, J F, Sakr, W, and Yoo, G H

Abstract

Objective/hypothesis: We examined whether p53 gene mutations were predictive of clinical behavior in laryngeal cancer.Study Design: Retrospective study of 45 patients with laryngeal cancer from 1985 to 1997.Methods: DNA was extracted from tumor tissue and subject to polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP) as well as DNA sequencing. The clinical outcome was correlated to the presence or absence of a p53 mutation.Results: The p53 gene was analyzed by direct DNA sequencing and was found to be mutated in 33% (15/45) of patients. The presence of a p53 mutation was associated with a significant improvement in overall survival (80% vs. 43%, P < .03) and a trend toward improved disease-free survival (87% vs. 60%, P = .08). When other prognostic factors were adjusted, multivariate analysis revealed a trend toward improvement in overall survival as well as disease-free survival.Conclusion: Depending on the location of a p53 mutation, the suppressive functions or clinical outcome may or may not be affected. Fifty-three percent of mutations were detected in nonconserved regions as opposed to 17% as reported in colon cancer. In colon cancer, mutations in conserved regions of the p53 gene predicted a poorer survival, whereas nonconserved gene mutations were not predictive. In our group of patients. p53 mutations predicted a better prognosis, which may be due to a large proportion of mutations that lie within nonconserved areas. The predictive power of p53 gene mutations may depend on functional loss and inactivation of highly conserved areas and must be tested in a prospective trial. [ABSTRACT FROM AUTHOR]

Published
1999

37. RE

Author

Fesseha, T., primary, Sakr, W., additional, Grignon, D., additional, Banerjee, M., additional, Wood, D. P., additional, and Pontes, J. E., additional

Published
1998
Full Text
View/download PDF

43. 8 Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer. Preliminary results of an intergroup randomized trial. Int 0099, SWOG 8892, RTOG 8817, ECOG 2388

Author

Giri, P.G., primary, LeBlanc, M., additional, Al-Sarraf, M., additional, Fu, K.K., additional, Cooper, J., additional, Vuong, T., additional, Forastiere, A., additional, Adams, G., additional, Sakr, W., additional, Schuller, D., additional, and Ensley, J., additional

Published
1996
Full Text
View/download PDF

50. Pathologic features the urologist should expect on a prostate biopsy.

Author

Che M, Sakr W, Grignon D, Che, Mingxin, Sakr, Wael, and Grignon, David

Abstract

In recent years, the pathological evaluation of prostate biopsy specimens has made great improvements in diagnostic accuracy and comprehensiveness. In this article, we review major pathological findings on prostate biopsy, their interpretation and reporting, as well as their clinical significance and utility. We discuss especially the clinically relevant histological features in either a positive or negative biopsy. We emphasize that both Gleason score and extent of cancer involvement in a needle core biopsy are important predictors of clinical outcome after either radical prostatectomy or radiation. Special issues regarding diagnosis and grading of minimal cancer on needle core biopsies are discussed. We also highlight the current standards on high-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on needle core biopsies. In summary, the pathology reports on needle biopsies are far beyond the simple presence or absence of cancer; they contain invaluable information to clinicians on patient management and counseling. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results